Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 62

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 7
Chunk 62
---
 month-over-month and quarter-over-quarter
growth. Tests processed in October 2025 continue the upward trend with completed tests representing a 111% increase over the monthly
average for the first nine months of 2025. Third-quarter sales volume increased 95% over the prior quarter. Medical centers ordering
multiple CyPath® Lung tests increased 106% in the third-quarter compared to the prior quarter and increased by 67% in
October compared to the 2025 year-to-date monthly average.

Patient
Case Studies

Detection
at Stage 1A followed by treatment offers a 95% 10-year survival rate as compared to the current overall 5-year survival rate of 26%,
according to a NEJM study. In addition to the three case studies reported in July, 2025, in which CyPath® Lung detected
lung cancer at Stage 1A when existing treatments can be curative, the Company released details in September, 2025 of four patient case
studies in which CyPath® Lung was the critical factor in clinical decision making, including instances in which cancer
was detected at Stage 1A.

On
September 26, 2025, the Company released details of three separate case studies – one in which use of CyPath® Lung
led to detecting lung cancer at Stage 1A, its earliest and possibly curative stage, and two where risky invasive procedures were avoided
for patients facing difficult healthcare choices.

On
September 9, 2025, the Company released details of a case in which CyPath® Lung identified lung cancer in a patient with
difficult-to-diagnose ground-glass pulmonary nodules which shifted the course of care from watchful waiting for up to 5 years to confirmed
malignancy and immediate treatment.

Appointment
of New Board Members

On
August 18, 2025, the Company announced the appointment of Roberto Rios, CPA, and John J. Oppenheimer, M.D., to its Board of Directors.
Mr. Rios has more than four decades of executive leadership in corporate finance and governance across industries including biotechnology
and medical devices, including financial leadership roles at ILEX Oncology, BioMedical Enterprises. Dr. Oppenheimer is the Director of
Clinical Research at Pulmonary and Allergy Associates and Clinical Professor of Medicine at Rutgers and a leader in the diagnosis and
treatment of asthma and COPD and an advisor to pharmaceutical companies focused on lung health.

Patent
Awards